

A value-of-information approach to sample size determination in confirmatory clinical trials in small populations

Nigel Stallard

Warwick Medical School, The University of Warwick, UK

www.warwick.ac.uk/InSPiRe



This project has received funding from the European Union's Seventh Framework Programme for research, technological development and demonstration under grant agreement number FP HEALTH 2013 – 602144.



Conventional sample size calculation:

fix type error rates due to concern about consequence of error

Alternative idea:

compare decisions in terms of - gains to patients

costs of observations

Big *n*: high prob. correct decision, high cost, few patients benefit Small *n*: low prob. correct decision, low cost, more patients benefit

Gains:

to patients receiving C to patients receiving E (for unknown treatment effect)

Costs:

fixed cost of trial
extra cost per patient in trial
extra cost for patients receiving E

These need to be on same scale

Choose optimal n and α

Example – trial in haemophilia A

Trial cost: \$1,000,000 + \$5,000/patient

Additional cost for new treatment: \$61,000

Prior for difference in probability of treatment success:


mean = 0.24, s.d = 0.12

Monetary value per treatment success \$400,000

Population size: 4,000


| n/2 $n/2$ | |
|-----------|-----------|
| 4n | 4000 - 5n |

Design optimization



Optimal design has n = 46 (23 per arm) $\alpha = 0.35$

Effect of population size



Smaller populations lead to smaller trials and larger α

Discussion

Trials in rare diseases do currently use smaller sample sizes

Value-of-information methods
could formalise ad-hoc sample size choice
modify sample size according to population size by
considering value of information gained
do not increase information available from small trial

Not the last word; but maybe the start of a conversation